Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$327.48

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $327.48 15

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $327.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $15.5112/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585003 CMS
Neurocrine Biosciences, Inc. $18.1411/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693124787 CMS
Indivior Inc. $16.0410/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775213 CMS
Alkermes, Inc. $12.1409/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585005 CMS
Alkermes, Inc. $14.0608/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585001 CMS
Janssen Pharmaceuticals, Inc $19.5708/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527621 CMS
Indivior Inc. $12.0707/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775211 CMS
JAZZ PHARMACEUTICALS INC. $12.7007/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684174127 CMS
Allergan Inc. $17.5207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271099 CMS
Indivior Inc. $20.1306/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775209 CMS
Takeda Pharmaceuticals U.S.A., Inc. $99.4705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682109013 CMS
Lundbeck LLC $12.3804/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684293419 CMS
Janssen Pharmaceuticals, Inc $25.0203/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527615 CMS
Alkermes, Inc. $18.5803/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686584999 CMS
Allergan Inc. $14.1501/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271096 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $400.00 12/31/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018817
Principal investigator 1 Allergan, Inc. $1,228.00 12/31/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 No dispute reported 06/30/2026 789018819
Principal investigator 1 Merck Sharp & Dohme Corporation $46.69 12/31/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 848764343
Principal investigator 1 Supernus Pharmaceuticals, Inc. $8,365.27 12/28/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 844990227
Principal investigator 1 Sage Therapeutics, Inc. $2,054.52 12/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837511411
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $13,258.00 12/21/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851032063
Principal investigator 1 Eisai Inc. $1,000.00 12/20/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836166641
Principal investigator 1 Eisai Inc. $500.00 12/20/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836166643
Principal investigator 1 Eisai Inc. $200.00 12/20/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836166645
Principal investigator 1 Purdue Pharma L.P. $513.00 12/20/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844882615
Principal investigator 1 Allergan, Inc. $1,980.00 12/16/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018813
Principal investigator 1 Allergan, Inc. $6.85 12/16/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018815
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,700.00 12/16/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851031473
Principal investigator 1 Sage Therapeutics, Inc. $1,192.81 12/16/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837511253
Principal investigator 1 Allergan, Inc. $7,036.45 12/14/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018809
Principal investigator 1 Allergan, Inc. $2,000.00 12/14/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018811
Principal investigator 1 Sage Therapeutics, Inc. $3,121.56 12/09/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837511191
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,230.00 12/06/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851031037
Principal investigator 1 Boehringer Ingelheim International GmbH $779.30 12/01/2021 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 828335325
Principal investigator 1 Boehringer Ingelheim International GmbH $217.06 12/01/2021 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 828335327
Principal investigator 1 Boehringer Ingelheim International GmbH $623.44 12/01/2021 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 828335329
Principal investigator 1 Boehringer Ingelheim International GmbH $623.44 12/01/2021 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 828335331
Principal investigator 1 Boehringer Ingelheim International GmbH $623.44 12/01/2021 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 828335333
Principal investigator 1 Purdue Pharma L.P. $1,026.00 12/01/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844882351
Principal investigator 1 Eli Lilly and Company $195.16 11/24/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 819460353
Principal investigator 1 Allergan, Inc. $1,700.00 11/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018801
Principal investigator 1 Allergan, Inc. $1,000.00 11/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018803
Principal investigator 1 Allergan, Inc. $1,000.00 11/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018805
Principal investigator 1 Allergan, Inc. $250.00 11/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018807
Principal investigator 1 Allergan, Inc. $1,700.00 11/15/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 No dispute reported 06/30/2026 789018799
Principal investigator 1 Allergan, Inc. $4,936.20 11/12/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018797
Principal investigator 1 Sage Therapeutics, Inc. $1,530.00 11/10/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837510645
Principal investigator 1 Sage Therapeutics, Inc. $22,110.27 11/10/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837510647
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,248.00 10/28/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 844175083
Principal investigator 1 Purdue Pharma L.P. $1,105.80 10/25/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844882187
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $13,741.75 10/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028517
Principal investigator 1 Eisai Inc. $3,170.00 10/15/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836166639
Principal investigator 1 Allergan, Inc. $9,044.95 10/13/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018795
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,750.00 10/07/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851027929
Principal investigator 1 Purdue Pharma L.P. $1,105.80 10/04/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844882077
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $14,490.35 09/27/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027583
Principal investigator 1 Janssen Research & Development, LLC $1,792.00 09/27/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664309
Principal investigator 1 Janssen Research & Development, LLC $2,075.45 09/27/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664325
Principal investigator 1 Sage Therapeutics, Inc. $3,568.50 09/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837509995
Principal investigator 1 Allergan, Inc. $15,676.90 09/14/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018793
Principal investigator 1 Allergan, Inc. $10,000.00 09/01/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 No dispute reported 06/30/2026 789018789
Principal investigator 1 Allergan, Inc. $500.00 09/01/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 No dispute reported 06/30/2026 789018791
Principal investigator 1 Purdue Pharma L.P. $8,624.10 09/01/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881921
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $11,424.70 08/31/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027099
Principal investigator 1 Allergan, Inc. $13,826.30 08/13/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018785
Principal investigator 1 Allergan, Inc. $1,167.55 08/13/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018787
Principal investigator 1 Sage Therapeutics, Inc. $4,063.41 08/11/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837509415
Principal investigator 1 Janssen Research & Development, LLC $10.99 08/09/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664239
Principal investigator 1 Janssen Research & Development, LLC $15,805.00 08/09/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664257
Principal investigator 1 Janssen Research & Development, LLC $2,612.00 08/09/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664275
Principal investigator 1 Janssen Research & Development, LLC $1,611.00 08/09/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664291
Principal investigator 1 Purdue Pharma L.P. $3,896.90 08/05/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881735
Principal investigator 1 Purdue Pharma L.P. $5,529.00 07/27/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881697
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $15,177.20 07/26/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026347
Principal investigator 1 Sage Therapeutics, Inc. $4,063.41 07/14/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837509159
Principal investigator 1 Allergan, Inc. $6,323.20 07/13/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018781
Principal investigator 1 Allergan, Inc. $3,443.75 07/13/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018783
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $837.50 07/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025827
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,934.00 07/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025829
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,493.40 07/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025965
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,000.00 07/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026019
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $600.00 07/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026021
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,000.00 07/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026023
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $6,041.05 06/29/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025421
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $12,592.25 06/29/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025423
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $20,444.00 06/29/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025425
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,000.00 06/17/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025263
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,250.00 06/17/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025265
Principal investigator 1 Sage Therapeutics, Inc. $14,698.71 06/16/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837508705
Principal investigator 1 Allergan, Inc. $5,726.60 06/15/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018777
Principal investigator 1 Allergan, Inc. $14,511.25 06/15/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018779
Principal investigator 1 Allergan, Inc. $237.95 06/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018775
Principal investigator 1 Purdue Pharma L.P. $10,562.10 06/02/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881493
Principal investigator 1 Sage Therapeutics, Inc. $15,784.98 05/27/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837508517
Principal investigator 1 Allergan, Inc. $11,170.10 05/17/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018773
Principal investigator 1 Sage Therapeutics, Inc. $3,433.95 05/12/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837508273
Principal investigator 1 Supernus Pharmaceuticals, Inc. $441.51 05/07/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 844987167
Principal investigator 1 Supernus Pharmaceuticals, Inc. $19,139.00 04/27/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 844986833
Principal investigator 1 Sage Therapeutics, Inc. $14,748.70 04/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837507979
Principal investigator 1 Purdue Pharma L.P. $4,322.50 04/20/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881375
Principal investigator 1 Sage Therapeutics, Inc. $17,772.30 04/14/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837507785
Principal investigator 1 Allergan, Inc. $11,104.55 04/13/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018771
Principal investigator 1 ITI, Inc. $100.00 04/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 830290167
Principal investigator 1 Supernus Pharmaceuticals, Inc. $4,250.00 04/08/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 844986321
Principal investigator 1 Purdue Pharma L.P. $9,206.45 04/06/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881335
Principal investigator 1 Eisai Inc. $1,600.00 03/31/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836166637
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,383.81 03/25/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 844985623
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,959.33 03/25/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 844985693
Principal investigator 1 Sage Therapeutics, Inc. $23,549.94 03/18/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837507311
Principal investigator 1 Allergan, Inc. $1,167.55 03/17/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789018769
Principal investigator 1 Sage Therapeutics, Inc. $3,733.47 03/17/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837507275
Principal investigator 1 ITI, Inc. $25,982.50 03/16/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 830289943
Principal investigator 1 Allergan, Inc. $18,280.85 03/15/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018767
Principal investigator 1 Sage Therapeutics, Inc. $8,284.19 03/04/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837507069
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $11,465.55 02/24/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 844173415
Principal investigator 1 Purdue Pharma L.P. $15,663.60 02/22/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 844881235
Principal investigator 1 Allergan, Inc. $31,747.10 02/15/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018765
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $778.05 02/11/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021695
Principal investigator 1 Sage Therapeutics, Inc. $26,415.03 02/11/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837506645
Principal investigator 1 Sage Therapeutics, Inc. $22,286.16 02/10/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837506567
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,683.70 02/04/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806256567
Principal investigator 1 ITI, Inc. $870.00 02/02/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia No dispute reported 06/30/2026 830288911
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,513.00 01/27/2021 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806256563
Principal investigator 1 Janssen Research & Development, LLC $10,847.00 01/21/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression No dispute reported 06/30/2026 787664223
Principal investigator 1 Allergan, Inc. $4,868.75 01/20/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789018763
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,641.30 01/19/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
ACP-103-055 No dispute reported 06/30/2026 837697107
Principal investigator 1 Sage Therapeutics, Inc. $4,558.32 01/19/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 837506251
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $778.05 01/14/2021 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851019825